Core Insights - Henry Schein reported its highest sales growth in 15 quarters, with fourth-quarter global sales reaching $3.4 billion, up 7.7% year over year, driven by strong performance across various segments [2][4][6]. Financial Performance - The company reported a fourth-quarter GAAP operating margin of 4.76%, down 10 basis points from the prior year, while the non-GAAP operating margin was 7.42%, remaining relatively flat year over year [1]. - Fourth-quarter GAAP net income was $101 million, or $0.85 per diluted share, compared to $94 million, or $0.74 per diluted share, in the prior-year period. Non-GAAP net income was $160 million, or $1.34 per diluted share, up from $149 million, or $1.19 per diluted share [7]. - Adjusted EBITDA for the fourth quarter was $291 million, an increase from $270 million, representing an 8.4% growth [7]. Segment Performance - Global specialty products saw sales growth of 14.6%, driven by strong performance in implants and biomaterials, with double-digit growth in value implants [10]. - Global technology sales grew 8.4%, supported by practice management software and significant growth in Dentrix Ascend, which surpassed 11,000 subscribers [11]. - The global distribution and value-added services group delivered 7.0% sales growth, with U.S. dental merchandise sales growing by 3.6% and U.S. dental equipment sales growing by 10.6% [8][9]. Leadership Transition - Fred Lowery will officially join as CEO next week, with a focus on a 100-day "listening tour" to validate existing initiatives and engage with stakeholders [3][6]. - Stanley Bergman will remain as Chairman of the Board, emphasizing Lowery's experience in scaling businesses through acquisitions and organic growth [4][6]. Strategic Initiatives - The company expects over $200 million of operating income improvement through cost savings and incremental gross margin opportunities, with an annual run-rate improvement of over $125 million by the end of 2026 [13]. - Henry Schein repurchased 2.8 million shares for $200 million at an average price of $71.10 per share, ending the year with approximately $780 million remaining under its authorization [14]. 2026 Outlook - For 2026, Henry Schein guided to sales growth of 3% to 5% and non-GAAP diluted EPS of $5.23 to $5.37, representing 5% to 8% growth compared to 2025 [15]. - The guidance assumes stable dental and medical end markets and consistent foreign exchange rates [15][16].

Core Insights - Henry Schein, Inc. reported strong fourth quarter sales growth, achieving the highest sales growth in 15 quarters, driven by global equipment, specialty products, and technology businesses [10][11] - The company is on track to exceed its goal of having over 50% of non-GAAP operating income from high-growth, high-margin businesses by the end of its strategic planning cycle in 2027 [11] - The implementation of the BOLD+1 strategic plan is progressing well, with significant advancements in e-commerce and innovative solutions for customer care [12][13] Financial Performance - Global sales for the fourth quarter reached $3.4 billion, reflecting a 7.7% growth compared to 2024, with constant currency sales growth of 5.8% [32] - Non-GAAP net income for the fourth quarter was $160 million, or $1.34 per diluted share, compared to $149 million, or $1.19 per diluted share in the prior year [34] - The effective tax rate for 2025 on a non-GAAP basis was 22.7%, slightly higher than the previous year's rate of 22% [33] Business Segments - The Global Distribution and Value Added Services Group saw sales growth of 7%, with U.S. dental merchandise sales growing by 3.6% and U.S. dental equipment sales increasing by 10.6% [35] - The Global Specialty Products Group experienced a sales increase of 14.6%, driven by strong performance in implants and biomaterials [38] - The Global Technologies Group reported total sales growth of 8.4%, with significant contributions from practice management software [38] Strategic Initiatives - The company is focusing on value creation initiatives expected to deliver over $200 million in operating income improvement over the next few years [39] - A new partnership with Amazon Web Services aims to integrate generative AI technology into Henry Schein's products, enhancing customer service and operational efficiency [29][30] - The rollout of the global e-commerce platform, henryschein.com, is expected to be completed for U.S. dental and Canadian customers in the first quarter of the year [12] Market Outlook - The U.S. dental market is showing signs of stability and positive growth, with patient traffic remaining stable and a favorable outlook for equipment investments [16][55] - International dental merchandise sales grew by 9.2%, benefiting from a weaker U.S. dollar and strong performance across various markets [23] - The company anticipates 2026 sales growth of 3% to 5% over 2025, with non-GAAP diluted EPS expected to be in the range of $5.23 to $5.37 [41]

Core Insights - Henry Schein, Inc. (HSIC) has a market capitalization of $8.4 billion and is a prominent global provider of healthcare products and services, primarily catering to dental and medical practitioners [1] - The company has experienced stock underperformance compared to the broader market, with a 7.4% increase in HSIC shares over the past 52 weeks, while the S&P 500 Index rose by 13.2% [2] - HSIC shares surged 10.8% following the announcement of third-quarter earnings that exceeded market expectations, with revenue of $3.34 billion, reflecting a year-over-year increase of 5.2% [4] Financial Performance - The company reported a non-GAAP EPS increase of 13.1% to $1.38, and adjusted EBITDA reached $295 million, up from $268 million in the previous year [5] - Management has raised its full-year 2025 non-GAAP EPS outlook to a range of $4.88–$4.96, anticipating sales growth of 3–4% [5] - Analysts project HSIC's adjusted EPS to grow 3.6% year-over-year to $4.91 for the fiscal year ending in December 2025 [6] Analyst Ratings - Among 15 analysts covering HSIC, the consensus rating is a "Moderate Buy," consisting of five "Strong Buy" ratings, nine "Holds," and one "Strong Sell" [6] - The current analyst configuration is more bullish than three months ago, with four "Strong Buy" ratings on the stock [7] - Leerink Partners analyst Michael Cherny reaffirmed a "Hold" rating on HSIC with a price target of $71 [7]